A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Isatuximab, Pomalidomide, and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed / Multiple Myeloma Refractory (RRMM)

被引：0

作者：

Niederwieser, Dietger ^{[1
]}

Richardson, Paul ^{[2
]}

Attal, Michel ^{[3
]}

Rajkumar, Vincent ^{[4
]}

San-Miguel, Jesus ^{[5
]}

Beksac, Meral ^{[6
]}

Spicka, Ivan ^{[7
]}

Leleu, Xavier ^{[8
]}

Schjesvold, Fredrik ^{[9
,10
]}

Moreau, Philippe ^{[11
]}

Dimopoulosu, Meletios ^{[12
]}

Huan, Jeffrey Shang-Yi ^{[13
]}

Minarik, Jiri ^{[14
]}

Cavo, Michele ^{[15
]}

Mace, Sandrine ^{[16
]}

Prince, H. Miles ^{[17
]}

Corzo, Kathryn P. ^{[18
]}

Campana, Frank ^{[18
]}

Le-Guennec, Solenn ^{[16
]}

Dubin, Franck ^{[16
]}

Anderson, Kenneth C. ^{[18
]}

机构：

[1] Univ Leipzig, Leipzig, Germany

[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[4] Mayo Clin, Rochester, MN USA

[5] Clin Univ Navarra, Navarra, Spain

[6] Ankara Univ, Ankara, Turkey

[7] Charles Univ Prague, Prague, Czech Republic

[8] CHRU Lille, Hop Claude Huriez, Lille, France

[9] Oslo Univ Hosp, Oslo Myeloma Ctr, Oslo, Norway

[10] Univ Oslo, KG Jebsen Ctr Cell Malignancies B, Oslo, Norway

[11] CHU Nantes, Nantes, France

[12] Natl & Kapodistrian Univ Athens, Athens, Greece

[13] Natl Taiwan Univ Hosp, Taipei, Taiwan

[14] Univ Hosp Olomouc, Olomouc, Czech Republic

[15] Univ Bologna, Bologna, Italy

[16] Sanofi R&D, Vitry Sur Seine, France

[17] Univ Melbourne, Epworth Healthcare & Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[18] Sanofi Genzyme Oncol, Cambridge, MA USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

482

引用

页码：40 / 41

页数：2

共 50 条

[1] A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
Richardson, Paul G.
Attal, Michel
Rajkumar, S. Vincent
San Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey S. Y.
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Mace, Sandrine
Corzo, Kathryn Penkus
Campana, Frank
Le-Guennec, Solenn
Dubin, Franck
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[2] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Attal, Michel
Richardson, Paul G.
Rajkumar, S. Vincent
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Mace, Sandrine
Corzo, Kathryn P.
Campana, Frank
Le-Guennec, Solenn
Dubin, Franck
Anderson, Kenneth C.
LANCET, 2019, 394 (10214): : 2096 - 2107
[3] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study (vol 394, pg 2096, 2019)
Attal, M.
Richardson, P. G.
Rajkumar, S., V
LANCET, 2019, 394 (10214): : 2072 - 2072
[4] Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
Richardson, Paul G.
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey S. Y.
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Mace, Sandrine
Malinge, Laure
Dubin, Franck
Morisse, Mony
Anderson, Kenneth C.
BLOOD, 2022, 140
[5] KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM).
Shah, Jatin J.
Jagannath, Sundar
Mateos, Maria-Victoria
Palumbo, Antonio
Kher, Uma
Marinello, Patricia Maria
San Miguel, Jesus
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[6] Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
Richardson, Paul
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Malinge, Laure
Dubin, Franck
Morisse, Mony
Anderson, Kenneth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S32 - S32
[7] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
Richardson, Paul G.
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Malinge, Laure
Dubin, Franck
van de Velde, Helgi
Anderson, Kenneth C.
LANCET ONCOLOGY, 2022, 23 (03): : 416 - 427
[8] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
Badros, Ashraf
Hyjek, Elizabeth
Ma, Ning
Lesokhin, Alexander
Dogan, Ahmet
Rapoport, Aaron P.
Kocoglu, Mehmet
Lederer, Emily
Philip, Sunita
Milliron, Todd
Dell, Cameron
Goloubeva, Olga
Singh, Zeba
BLOOD, 2017, 130 (10) : 1189 - 1197
[9] MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM)
San-Miguel, Jesus F.
Weisel, Katja C.
Moreau, Philippe
Lacy, Martha
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Banos, Anne
Rocafiguera, Albert Oriol
Yu, Xin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[10] KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma
Mateos, M. V.
Blacklock, H.
Rocafiguera, A. O.
Iida, S.
Jagannath, S.
Lonial, S.
Kher, U.
Farooqui, M.
Marinello, P.
San-Miguel, J.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →